Fsd Pharma Announced Submission Of Clinical Trial Application For Phase-1b Trial Named Metal-1 To Assess Safety And Efficacy Of Unbuzzd In Healthy Volunteers Under Alcohol Intoxication; Submitted For Ethics Review In Australia; Volunteer Recruitment Expected To Start In April Pending Approval
Portfolio Pulse from Benzinga Newsdesk
FSD Pharma announced the submission of a clinical trial application for a Phase-1b trial, METAL-1, to assess the safety and efficacy of Unbuzzd in healthy volunteers under alcohol intoxication. The application has been submitted for ethics review in Australia, with volunteer recruitment expected to start in April pending approval.
March 11, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FSD Pharma's submission of the METAL-1 trial application for Unbuzzd could positively impact investor sentiment, especially if the trial proceeds as planned.
The submission of the METAL-1 trial application by FSD Pharma is a significant step towards advancing the company's product pipeline. Positive outcomes from the trial, especially in a novel area like mitigating alcohol intoxication, could significantly enhance the company's valuation and investor interest. The anticipation of volunteer recruitment starting in April adds a time-sensitive aspect to this news, potentially affecting the stock price positively in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90